Latest Ribavirin Stories
SAN DIEGO, June 1, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced issuance of the U.S. patent covering setrobuvir (ANA598), the Company's Direct-Acting Antiviral (DAA) in Phase IIb development for chronic hepatitis C virus infection (HCV). U.S. Patent No.
PRINCETON, N.J., May 26, 2011 /PRNewswire/ -- Pharmasset, Inc.
Vertex Pharmaceuticals Inc's highly anticipated hepatitis C drug has finally won US approval, which will usher in a new marketing battle with a rival medicine from Merck & Co.
SILVER SPRING, Md., May 23, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Incivek (telaprevir) to treat certain adults with chronic hepatitis C infection.
HUDDINGE, Sweden, May 20, 2011 /PRNewswire/ -- - All TMC435 Patient Subgroups Achieved Substantially Higher SVR4 Rates (Undetectable Virus 4 Weeks After End of Treatment) Compared to pegylated-interferon and ribavirin Alone - TMC435 was Safe and Well Tolerated at All Doses and Treatment Durations Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced results from the ASPIRE phase 2b study that...
WHITEHOUSE STATION, N.J., May 14, 2011 /PRNewswire/ -- Merck (NYSE: MRK) (known as MSD outside the United States and Canada) announced today that the U.S.
SILVER SPRING, Md., May 13, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Victrelis (boceprevir) to treat certain adults with chronic hepatitis C.
Research being presented at Digestive Disease WeekÂ® (DDW) shows that screening individuals for hepatitis C based on age instead of conventional risk factors may help increase detection rates as well as prevent liver disease.
SAN DIEGO, May 9, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD) announces that it has submitted a request to the U.S.
Screening for hepatitis C based on age instead of conventional risk factors may help improve detection rates and prevent liver disease.
Lassa fever, first described in 1969 in Lassa, is an acute viral hemorrhagic fever. Clinical cases were known a decade before this but were not associated with this viral pathogen. It is endemic in West African countries and causes approximately 5,000 deaths. The Natal Multimammate Mouse is the primary animal host. The rodent is a source of protein but the virus is usually transmitted by the contact with the feces and urine of animals accessing grain stores in residences. The lassa virus...
- A gift; a largess; a gratuity; a present; a dole.